Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation

Molecular Medicine Reports

Volumn 8, Issue 2, 2013, Pages 439-445

  Shi, Lijuan ^a   Shi, Lei ^b   Zhang, Hefang ^a   Hu, Zhijuan ^a,c   Wang, Chao ^c   Zhang, Donghui ^c   Song, Guangyao ^a,c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Chemical and Pharmaceutical Vocational Technology College   (China)

^c HEBEI GENERAL HOSPITAL   (China)

Author keywords

CPT1A; Insulin resistance; Lipid metabolism imbalance; MTTP; NAFLD; Oxymatrine; PPAR

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; FATTY ACID; FENOFIBRATE; FRUCTOSE; INSULIN; LIPID; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OXYMATRINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY LIVER; GENE ACTIVATION; GENE EXPRESSION; GLUCOSE INFUSION; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; FATTY LIVER; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIPIDS; LIVER; MALE; ORGAN SIZE; PPAR ALPHA; QUINOLIZINES; RATS;

RATTUS; SOPHORA FLAVESCENS;

EID: 84879975014     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1512     Document Type: Article

References (29)

1. Tiniakos DG, Vos MB and Brunt EM: Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5: 145-171, 2010.
2. Sheng L, Cho KW, Zhou Y, et al: Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation. J Biol Chem 286: 38128-38135, 2011.
3. Utzschneider KM and Kahn SE: Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91: 4753-4761, 2006.
4. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW and Klein S: Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134: 424-431, 2008.
5. Smith BW and Adams LA: Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 48: 97-113, 2011.
6. Gaemers IC, Stallen JM, Kunne C, et al: Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim Biophys Acta 1812: 447-458, 2011.
7. Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature 405: 421-424, 2000.
8. Améen C, Edvardsson U, Ljungberg A, et al: Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 280: 1224-1229, 2005.
9. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ and Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50: 411-417, 2001.
10. Seo YS, Kim JH, Jo NY, et al: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 23: 102-109, 2008.
11. Cui X, Wang Y, Kokudo N, Fang D and Tang W: Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 4: 39-47, 2010.
12. Cao YG, Jing S, Li L, et al: Antiarrhythmic effects and ionic mechanisms of oxymatrine from Sophora flavescens. Phytother Res 24: 1844-1849, 2010.
13. Deng ZY, Li J, Jin Y, Chen XL and Lü XW: Effect of oxymatrine on the p38 mitogen-activated protein kinases signalling pathway in rats with CCl4 induced hepatic fibrosis. Chin Med J (Engl) 122: 1449-1454, 2009.
14. Zeng XY, Zhou X, Xu J, et al: Screening for the efficacy on lipid accumulation in 3T3-L1 cells is an effective tool for the identification of new anti-diabetic compounds. Biochem Pharmacol 84: 830-837, 2012.
15. Yuan LJ, Lu X, Wang J, Zheng TZ, Qu SY and Zhang XY: Effects of matrine on weight, serum lipids and anti-oxidative capacity in high-fatted rats. Lishizhen Medicine and Materia Medica Research 9: 2062-2064, 2008.
16. Zhang HF, Shi LJ, Song GY et al: Protective effects of matrine against progression of high-fructose diet-induced steatohepatitis by enhancing antioxidant and anti-inflammatory defences involving Nrf2 translocation. Food Chem Toxicol 55: 70-77, 2013.
17. Xing Y, Yan F, Liu Y, Liu Y and Zhao Y: Matrine inhibits 3T3-L1 preadipocyte differentiation associated with suppression of ERK1/2 phosphorylation. Biochem Biophys Res Commun 396: 691-695, 2010.
18. Thorburn AW, Storlien LH, Jenkins AB, Khouri S and Kraegen EW: Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 49: 1155-1163, 1989.
19. Ren LP, Chan SM, Zeng XY, et al: Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. PLoS One 7: e30816, 2012.
20. Kraegen EW, James DE, Bennett SP and Chisholm DJ: In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am J Physiol 245: E1-E7, 1983.
21. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD and Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351, 2005.
22. Postic C and Girard J: Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838, 2008.
23. Chou CJ, Haluzik M, Gregory C, et al: WY14, 643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 277: 24484-24489, 2002.
24. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R and Leclercq I: Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38: 123-132, 2003.
25. Kohjima M, Enjoji M, Higuchi N, et al: Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20: 351-358, 2007.
26. Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF and O'Doherty RM: A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 294: E969-E977, 2008.
27. Wetterau JR and Zilversmit DB: A triglyceride and cholesteryl ester transfer protein associated with liver microsomes, J Biol Chem 259: 10863-10866, 1984.
28. Stefano JT, de Oliveira CP, Corrêa-Giannella ML, et al: Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig Dis Sci 52: 3448-3454, 2007.
29. Chen Z, Newberry EP, Norris JY, et al: ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob mice. J Lipid Res 49: 2013-2022, 2008. Department of Science and Technology